Infant Bacterial Therapeutics AB logo

IBT B - Infant Bacterial Therapeutics AB News Story

SEK113.6 14.6  14.8%

Last Trade - 3:05pm

Sector
Healthcare
Size
Small Cap
Market Cap £95.0m
Enterprise Value £58.8m
Revenue £n/a
Position in Universe 917th / 1836

Infant Bacterial Therapeutics publishes Annual Report for 2020

Fri 9th April, 2021 7:00am
For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20210409:nGNE2mlZb2&default-theme=true


Infant Bacterial Therapeutics AB (publ) has today published the Annual Report
for 2020.

The report is available on IBT’s website ibtherapeutics.com
(https://www.globenewswire.com/Tracker?data=gm-DivdQbEF2L3H2_Px-9ztu9FVhuZQdvn6nbhKTZBwaAfaF9jHp5Bto_572W7kMgb8KoFNnm2HnALJEuAwKGJT-s_nZ_SEPtwhELvJjZ4I=) under
the section “Investors & Media – Financial Reports” and is available in
printed form for those that have requested. A copy can be requested by
contacting IBT’s office via info@ibtherapeutics.com.

About Infant Bacterial Therapeutics AB
Infant Bacterial Therapeutics AB (publ) is a pharmaceutical company with a
product in clinical stage with a vision to develop drugs influencing the
infant microbiome, and thereby prevent or treat rare diseases affecting
infants.

IBT is currently developing the drug candidate IBP-9414, for the prevention of
necrotizing enterocolitis (“NEC”) and improvement of feeding tolerance in
premature infants. IBP-9414 contains the active substance Lactobacillus
reuteri, which is a human bacterial strain naturally present in breast milk.
The product portfolio also includes another project, IBP-1016, for the
treatment of gastroschisis, a severe and rare disease affecting infants. By
developing these drugs, IBT has the potential to fulfill unmet needs for
diseases where there are currently no prevention or treatment therapies
available.

Infant Bacterial Therapeutics AB (“IBT”) is a public company domiciled in
Stockholm. The company’s class B-shares shares are listed on Nasdaq
Stockholm, Mid-cap (IBT B).

For additional information please contact 
Staffan Strömberg, CEO
Daniel Mackey, CFO
Infant Bacterial Therapeutics AB
Bryggargatan 10
111 21 Stockholm
Phone: +46 70 670 1226
info@ibtherapeutics.com
www.ibtherapeutics.com

Publication

The information was submitted for publication, through the agency of the
contact persons set out above, at 08:00 CET on April 9, 2021. 

 

Attachments
*     PR 20210409 AR ENG
(https://ml-eu.globenewswire.com/Resource/Download/a3f2fd75-1695-4055-8e63-38984cccad6a)
  
*     IBTAR2020ENG20210329
(https://ml-eu.globenewswire.com/Resource/Download/e7576f15-a36d-4d8b-bc5f-b8bf73a37dd5)
  
*     IBTAR2020SWE 20200407
(https://ml-eu.globenewswire.com/Resource/Download/bd281759-cd50-4cbb-99b2-e6b2e8a912fd)
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.